US20200305723A1 - Minimally invasive collection probe and methods for the use thereof - Google Patents

Minimally invasive collection probe and methods for the use thereof Download PDF

Info

Publication number
US20200305723A1
US20200305723A1 US16/882,801 US202016882801A US2020305723A1 US 20200305723 A1 US20200305723 A1 US 20200305723A1 US 202016882801 A US202016882801 A US 202016882801A US 2020305723 A1 US2020305723 A1 US 2020305723A1
Authority
US
United States
Prior art keywords
conduit
probe
aspects
tissue
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/882,801
Other languages
English (en)
Inventor
Livia Schiavinato Eberlin
Thomas Milner
Jialing ZHANG
Noah Giese
Nitesh Katta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Priority to US16/882,801 priority Critical patent/US20200305723A1/en
Assigned to BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM reassignment BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MILNER, THOMAS, KATTA, NITESH, GIESE, Noah, SCHIAVINATO EBERLIN, Livia, ZHANG, JIALING
Publication of US20200305723A1 publication Critical patent/US20200305723A1/en
Priority to US17/453,740 priority patent/US11737671B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/4055—Concentrating samples by solubility techniques
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B1/00—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
    • A61B1/313—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor for introducing through surgical openings, e.g. laparoscopes
    • A61B1/3132—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor for introducing through surgical openings, e.g. laparoscopes for laparoscopy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
    • A61B10/02—Instruments for taking cell samples or for biopsy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
    • A61B10/02—Instruments for taking cell samples or for biopsy
    • A61B10/0233—Pointed or sharp biopsy instruments
    • A61B10/0283—Pointed or sharp biopsy instruments with vacuum aspiration, e.g. caused by retractable plunger or by connected syringe
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
    • A61B10/02—Instruments for taking cell samples or for biopsy
    • A61B10/04—Endoscopic instruments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/28—Surgical forceps
    • A61B17/29—Forceps for use in minimally invasive surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/34—Trocars; Puncturing needles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B34/00—Computer-aided surgery; Manipulators or robots specially adapted for use in surgery
    • A61B34/30—Surgical robots
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0075—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
    • A61M25/0023—Catheters; Hollow probes characterised by the form of the tubing by the form of the lumen, e.g. cross-section, variable diameter
    • A61M25/0026—Multi-lumen catheters with stationary elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/4833—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00—Particle spectrometers or separator tubes
    • H01J49/02—Details
    • H01J49/04—Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locks; Arrangements for external adjustment of electron- or ion-optical components
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00—Particle spectrometers or separator tubes
    • H01J49/02—Details
    • H01J49/04—Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locks; Arrangements for external adjustment of electron- or ion-optical components
    • H01J49/0404—Capillaries used for transferring samples or ions
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00—Particle spectrometers or separator tubes
    • H01J49/02—Details
    • H01J49/04—Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locks; Arrangements for external adjustment of electron- or ion-optical components
    • H01J49/0431—Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locks; Arrangements for external adjustment of electron- or ion-optical components for liquid samples
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00—Particle spectrometers or separator tubes
    • H01J49/02—Details
    • H01J49/04—Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locks; Arrangements for external adjustment of electron- or ion-optical components
    • H01J49/0459—Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locks; Arrangements for external adjustment of electron- or ion-optical components for solid samples
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00—Particle spectrometers or separator tubes
    • H01J49/02—Details
    • H01J49/10—Ion sources; Ion guns
    • H01J49/16—Ion sources; Ion guns using surface ionisation, e.g. field-, thermionic- or photo-emission
    • H01J49/165—Electrospray ionisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
    • A61B10/02—Instruments for taking cell samples or for biopsy
    • A61B10/06—Biopsy forceps, e.g. with cup-shaped jaws
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
    • A61B2090/3937—Visible markers
    • A61B2090/395—Visible markers with marking agent for marking skin or other tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
    • A61B2090/3983—Reference marker arrangements for use with image guided surgery

Definitions

  • the present invention relates generally to the field of medicine, molecular biology and biochemistry. More particularly, it concerns methods and devices for assessment of tissue samples using mass spectrometry.
  • Tissue evaluation is very critical in the diagnosis and management of cancer patients.
  • Intra-operative pathologic assessment of excised tissues is routinely performed for diagnosis and surgical margin evaluation in a variety of cancer surgeries.
  • the resected tissue specimens are sent to a nearby room, often called the “frozen room”, for tissue preparation, staining, and evaluation.
  • the tissue specimen is frozen, sectioned, stained, and interrogated using light microscopy by an expert pathologist who carefully evaluates if the surgical margins contain cancer cells (positive margin) or not (negative margin). While intraoperative frozen section analysis has been performed in clinical practice for decades, it presents many challenges.
  • a method for obtaining a mass spectrometry profile comprising using a probe to apply a fixed or discrete volume of a solvent to an assay site (e.g., a tissue site); using the probe to collect the applied solvent to obtain a liquid sample; and subjecting the liquid sample to mass spectrometry analysis.
  • a method for assessing tissue samples comprising obtaining a plurality of liquid samples from a plurality of tissue sites in a subject and subjecting the plurality of liquid samples to mass spectrometry.
  • Still a further embodiment provides an apparatus for obtaining or producing samples (e.g., from tissues) for mass spectrometry analysis, the apparatus comprising: a chamber comprising a solvent; a gas supply (e.g., a pressurized gas supply); a mass spectrometer; a probe comprising a reservoir, a first conduit, a second conduit and a third conduit, wherein: the reservoir is in fluid communication with the first conduit, the second conduit and the third conduit; the first (solvent) conduit is in fluid communication with the chamber; the second (gas) conduit is in fluid communication with a gas supply; and the third (collection) conduit is in fluid communication with the mass spectrometer.
  • the gas supply can be a pressurized gas supply.
  • the probe is, or is comprised in, the cannula of a surgical instrument.
  • the surgical instrument may be a laparoscope, trocar needle, biopsy guide, or multiple-lumen catheter.
  • the surgical instrument manually operated.
  • the surgical instrument is robotic.
  • the probe comprises a distal probe end and the distal probe end comprises a shutter that can be closed to prevent fluid communication outside of the probe.
  • the shutter is a balloon that can be inflated to prevent fluid communication outside of the probe.
  • the balloon can be inflated with a gas or a liquid.
  • the shutter is a door that can be closed to prevent fluid communication outside of the probe.
  • the shutter is configured such that is can be opened and closed multiple times. The shutter may be controlled manually or robotically.
  • the first, second or third conduit is more than 1 meter in length.
  • the first conduit is in fluid communication with the third conduit; and the second conduit is in fluid communication with the third conduit.
  • the first conduit is disposed within the third conduit.
  • the second conduit is disposed within the third conduit.
  • the first conduit and the second conduit are disposed within the third conduit.
  • the first conduit comprises a first distal end; the second conduit comprises a second distal end; the third conduit comprises a third distal end; and the first distal end and the second distal end are located within the third conduit.
  • the third distal end is located within the probe.
  • the first distal end is located a first distance from the distal probe end; the second distal end is located a second distance from the distal probe end; the third distal end is located a third distance from the distal probe end; the first distance is greater than the third distance; and the second distance is greater than the third distance.
  • the first distal end and the second distal end terminate proximal to a sample collection region of the third conduit.
  • the sample collection region is located between the first and second distal ends and the third distal end.
  • the sample collection region is in fluid communication with the mass spectrometer via the third conduit.
  • the apparatus further comprises a control system configured to control; a solvent flow from the chamber through the first conduit to the first distal end; a gas flow from the gas supply through the second conduit to the second distal end; and a sample flow through the third conduit to the mass spectrometer.
  • the apparatus may additionally comprise a fourth conduit, wherein the first conduit, the second conduit and the third conduit are each in fluid communication with the fourth conduit.
  • the apparatus may further comprise a first valve configured to control flow between the first conduit and the fourth conduit; and a second valve configured to control flow between the second conduit and the fourth conduit.
  • the apparatus may further comprise a third first valve configured to control flow between the third conduit and the fourth conduit.
  • the gas supply provides air, nitrogen or carbon dioxide to the probe.
  • the gas supply is a pressurized gas supply that provides a gas to the probe at a pressure between 0.1 psig and 5.0 psig.
  • the pressurized gas supply provides a gas to the probe at a pressure between 0.5 psig and 2.5 psig. In specific aspects, the pressurized gas supply provides a gas to the probe at a pressure less than 100 psig.
  • the gas for use in an apparatus of the embodiments may be provided by a pressurized gas supply.
  • the gas can be pumped into an apparatus.
  • the gas can be pulled through an apparatus by use of a vacuum.
  • the vacuum is provided by the mass spectrometer inlet.
  • an additional vacuum system is employed.
  • the gas supply is preferably a pressurized gas supply.
  • the solvent comprises water. In more specific aspects, the solvent comprises sterile water. In several aspects, the solvent comprises ethanol. In certain specific aspects, the solvent comprises an aqueous mixture including from 1 to 25% ethanol.
  • the probe comprises a tracking device or dye to track a location of the probe.
  • the apparatus may further comprise a control system configured to control: a solvent flow from the chamber through the first conduit; a gas flow from the gas supply through the second conduit; and a sample flow through the third conduit to the mass spectrometer.
  • the control system is configured to: control the solvent flow at a flow rate between 200 and 5000 microliters per minute for a period of time between 1 and 3 seconds; control the gas flow at a flow rate between 0.1 and 15 psig for a period of time between 5 and 50 seconds; and/or control the sample flow for a period of time between 5 and 50 seconds.
  • the control system comprises programming that initiates solvent flow.
  • the mass spectrometer is in electronic communication with a computer that can provide sample analysis.
  • the computer provides a visual or auditory read-out of the sample analysis.
  • the apparatus may additionally comprise a waste container in fluid communication with the third conduit.
  • the apparatus may further comprise a valve configured to diverge a fluid from the third conduit to the waste container.
  • the apparatus may further comprise a pump configured to remove contents of the waste container.
  • the apparatus may comprise a pump in fluid communication with the third conduit.
  • the pump is configured to increase the velocity of the contents within the third conduit.
  • the apparatus may further comprise a heating element coupled to the third conduit. In a specific aspect, the heating element is a heating wire.
  • the apparatus may comprise an ionization device in fluid communication with the third conduit.
  • the ionization device is an electrospray ionization (ESI) device.
  • the ionization device is an atmospheric pressure chemical ionization (APCI) device.
  • the ionization device is to form a spray proximal to an inlet for mass spectrometer.
  • the third conduit is not directly coupled to the mass spectrometer.
  • the apparatus may further comprise a venturi device in fluid communication with the third conduit. In certain aspects, the apparatus does not include device for application of ultrasonic or vibrational energy.
  • a method for assessing tissue samples from a subject comprising (a) applying a fixed or discrete volume of a solvent to a tissue site in the subject through the cannula of a surgical instrument; (b) collecting the applied solvent to obtain a liquid sample; and (c) subjecting the sample to mass spectrometry analysis.
  • the fixed or discrete volume of a solvent is not applied as a spray.
  • the fixed or discrete volume of a solvent is applied as a droplet.
  • the surgical instrument is a laparoscope, trocar needle, or biopsy guide. The surgical instrument may be manually operated or robotic.
  • the cannulas comprised in a probe having a distal probe end and the distal probe end comprises a shutter that can be closed to prevent fluid from passing out of the cannula of the probe.
  • the shutter is a balloon that can be inflated to prevent fluid communication outside of the probe.
  • the balloon can be inflated with a gas.
  • the shutter is a door than can be closed to prevent fluid communication outside of the probe.
  • the shutter can be an iris diaphragm, a mechanical closure, gate, or tapenade.
  • the shutter can be manually controlled or may be automated.
  • the shutter may be on a timer that activates the shutter after solvent has been in contact with the tissue site for a predetermined time period (e.g., at least about 1, 2, or 3 seconds).
  • a predetermined time period e.g., at least about 1, 2, or 3 seconds.
  • the fixed or discrete volume of a solvent is applied at using a pressure of less than 100 psig.
  • the fixed or discrete volume of a solvent is applied at using a pressure of less than 10 psig.
  • the fixed or discrete volume of a solvent is applied using a mechanical pump to move the solvent through a solvent conduit.
  • collecting the applied solvent comprises applying a negative pressure to pull the sample into a collection conduit and/or applying a gas pressure to push the sample into a collection conduit.
  • collecting the applied solvent comprises applying a negative pressure to pull the sample into a collection conduit and applying a positive pressure to push the sample into a collection conduit.
  • the solvent is applied through a solvent conduit that is separate from the collection conduit.
  • the gas pressure is applied through a gas conduit that is separate from the solvent conduit and the collection conduit.
  • applying a gas pressure to push the sample into a collection conduit comprises applying a pressure of less than 100 psig.
  • the method produces no detectable physical damage to the tissue. In some aspects, the method does not involve application of ultrasonic or vibrational energy to the tissue.
  • the solvent may be sterile. In specific aspects, the solvent may be a pharmaceutically acceptable formulation, and further an aqueous solution, and still further sterile water. In further specific aspects, the solvent consists essentially of water. In other aspects, the solvent comprises from about 1 to 20% of an alcohol. In some aspects, the alcohol comprises ethanol. In still additional aspects, the discrete volume of solvent is between about 0.1 and 100 ⁇ L. In certain aspects, the discrete volume of solvent is between about 1 and 50 ⁇ L. In further aspects, collecting the applied solvent is between 0.1 and 30 seconds after the applying step. In another aspect, collecting the applied solvent is between 1 and 10 seconds after the applying step. In some aspects, the tissue site in an internal tissue site that is being surgically assessed.
  • the method additionally comprises collecting a plurality liquid samples from a plurality of tissue sites.
  • the liquid samples are collected with a probe.
  • the probe is washed between collection of the different samples.
  • the probe is disposable and is changed between collection of the different samples.
  • the probe comprises a collection tip and further comprising ejecting the collection tip from the probe after the liquid samples are collected.
  • the plurality of tissue sites comprises 2, 3, 4, 5, 6, 7, 8, 9 or 10 tissues sites.
  • the plurality of tissue sites surrounds a section of tissue that has been surgically resected.
  • the resected tissue is a tumor.
  • the method is further defined as an intraoperative or post operative method.
  • the mass spectrometry comprises ambient ionization MS.
  • subjecting the sample to mass spectrometry analysis comprises determining a profile corresponding to the tissue site.
  • the method comprises comparing the profile to a reference profile to identify tissue sites that include diseased tissue.
  • Still a further aspect comprises resecting tissue sites that are identified to include diseased tissue.
  • the method is performed using an apparatus in accordance with the embodiments and aspects described above.
  • the mass spectrometer is in communication with a computer that provides a sample analysis.
  • the results of each sample analysis are provided by a visual or auditory output from the computer.
  • the results of each sample analysis by the computer can be indicated by a differently colored light that is illuminated or by a different frequency of sound produced.
  • the mass spectrometer is a mobile the mass spectrometer.
  • the mass spectrometer can comprise an uninterruptable power supply (e.g., a battery power supply).
  • the mass spectrometer comprises an inlet that may be closed to keep instrument vacuum.
  • the mass spectrometer is separated from the probe by a mesh filter (e.g., to block contamination).
  • the reservoir is configured to form a droplet of the solvent.
  • the pressurized gas supply provides a gas to the probe at a pressure between 0.1 psig and 5.0 psig. In further aspects, the pressurized gas supply provides a gas to the probe at a pressure between 0.5 psig and 2.5 psig. In several aspects, the pressurized gas supply provides air to the probe. In other aspects, the pressurized gas supply provides an inert gas such as nitrogen or carbon dioxide to the probe. In some aspects, a gas supply for use according to the embodiments is at atmospheric pressure. For example, the conduit for delivery of gas may be supplied by the atmosphere around the apparatus.
  • the apparatus further comprises a pump configured to transfer the solvent from the chamber to the first conduit.
  • the apparatus may comprise a first valve configured to control a flow from the third conduit to the mass spectrometer.
  • the third conduit is under a vacuum when the first valve is in the open position.
  • the apparatus may comprise a second valve configured to control a flow of gas (e.g., pressurized gas) through the second conduit.
  • the solvent may comprise water and/or ethanol.
  • the probe is formed from polydimethylsiloxane (PDMS) and/or polytetrafluoroethylene (PTFE).
  • the probe is disposable.
  • the probe may include a collection tip that is ejectable (e.g. capable of being ejected from the probe).
  • the probe comprises a tracking device configured to track a location of the probe.
  • the reservoir has a volume between 1 microliter and 500 microliters, between about 1 microliter and 100 microliters or between about 2 microliters and 50 microliters. In additional aspects, the reservoir has a volume between 5.0 microliters and 20 microliters.
  • the apparatus may additionally comprise a control system configured to control: a solvent flow (e.g., flow of a fixed or discrete volume of solvent) from the chamber through the first conduit to the reservoir; a gas flow from the gas supply through the second conduit to the reservoir; and a sample flow from the reservoir through the third conduit to the mass spectrometer.
  • the control system is configured to: control the solvent flow at a flow rate between 100 and 5000 microliters per minute (e.g., between 200 and 400 microliters per minute) for a period of time between 1 and 3 seconds; control the gas flow at a flow rate between 1 and 10 psig for a period of time between 10 and 15 seconds; and control the sample flow for a period of time between 10 and 15 seconds.
  • control system comprises a trigger or button to initiate solvent flow.
  • control system comprises a pedal (i.e., that can be operated by foot action) to initiate solvent flow.
  • the control system is configured to control: a solvent flow (e.g., flow rate for a fixed period of time) from the chamber through the first conduit to the reservoir.
  • a solvent flow e.g., flow rate for a fixed period of time
  • an apparatus of the embodiments does not include a device for producing ultrasonic or vibrational energy (e.g., in sufficient amounts to disrupt tissues).
  • a further embodiment provided a method for assessing tissue samples from a subject comprising applying a solvent to a tissue site on the subject, collecting the applied solvent to obtain a liquid sample, and subjecting the sample to mass spectrometry analysis.
  • the solvent may be sterile.
  • the solvent is pharmaceutically acceptable formulation.
  • the solvent is an aqueous solution.
  • the solvent may be sterile water or consist essentially of water.
  • the solvent may comprise from about 1% to 5%, 10%, 15%, 20%, 25% or 30% of an alcohol.
  • the solvent comprises 0.1% to 20% of an alcohol, 1% to 10% of an alcohol or 1% to 5% 1% to 10% of an alcohol (e.g., ethanol).
  • the alcohol may be ethanol.
  • applying the solvent to the tissue comprises applying a discrete volume of solvent to the tissue site.
  • the solvent is applied in a single droplet.
  • the solvent is applied in a discrete number of droplets from 1 to 10.
  • the solvent is applied to the sample from the reservoir via a channel independent of the gas.
  • the solvent is applied to the sample under low pressure.
  • the solvent is applied by a mechanical pump such that solvent is applied to the tissue site (e.g., moved into a reservoir where it is in contact with the tissue site) with minimal force thereby exerting minimal pressure (and producing minimal damage) at a tissue site.
  • the low pressure may be less than 100 psig, less than 90 psig, less than 80 psig, less than 70 psig, less than 60 psig, less than 50 psig, or less than 25 psig. In some embodiments, the low pressure is from about 0.1 psig to about 100 psig, from about 0.5 psig to about 50 psig, from about 0.5 psig to about 25 psig, or from about 0.1 psig to about 10 psig. In particular aspects, the discrete volume of solvent is between about 0.1 and 100 or between about 1 and 50 ⁇ L. In further aspects, collecting the applied solvent is between 0.1 and 30 seconds after the applying step.
  • collecting the applied solvent is between 1 and 10 seconds after the applying step (e.g., at least 1, 2, 4, 5, 6, 7, 8 or 9 seconds).
  • a method of the embodiments does not involve application of ultrasonic or vibrational energy to a sample or tissue.
  • a method of the embodiments comprises applying a fixed or discrete volume of a solvent (e.g., using mechanical pump) to a tissue site through a solvent conduit.
  • the fixed or discrete volume of a solvent is moved through a solvent conduit into a reservoir where it is in direct contact with a tissue site (e.g., for 0.5-5.0 seconds).
  • collecting the applied solvent comprises applying a negative pressure to pull the sample into a collection conduit and/or applying a gas pressure to push the sample into a collection conduit.
  • the solvent is applied through a solvent conduit that is separate from the collection conduit.
  • a gas pressure is applied to push the sample into the collection conduit the gas pressure is applied through a gas conduit that is separate from the solvent conduit and the collection conduit.
  • the applied gas pressure of less than 100 psig.
  • the gas pressure is preferably less than 10 psig, such as 0.1 to 5 psig.
  • a method of the embodiments is defined as producing no detectable physical damage to the tissue being assessed.
  • the method may additionally comprise collecting a plurality liquid samples from a plurality of tissue sites.
  • the device e.g., the probe
  • a device used to collect the samples includes a disposable collection tip (probe) that can be changed between each sample collection.
  • the collection tip may be ejectable (e.g. capable of being ejected from the device).
  • the plurality of tissue sites comprise 2, 3, 4, 5, 6, 7, 8, 9, 10 or more tissues sites in vivo.
  • the plurality of tissue sites surround a section of tissue that has been surgically resected (e.g., ex vivo).
  • the resected tissue is a tumor.
  • the method may be defined as an intraoperative method.
  • a further embodiment provides a method of identifying a sampled tissue site and a method to communicate location of the site to the device (probe) operator.
  • Identification of a sampled tissue site allows the operator to access the molecular information recorded at sampled tissue site at a time after sampling molecules collected from the tissue.
  • At least three types of identification approaches are recognized.
  • an exogenous material is attached to the sampled tissue site that identifies the sampled molecular information.
  • the device (probe) is equipped with a tracking sensor/emitter that allows recording the location of the probe (device) and communication to an imaging device when the molecular information is sampled.
  • the tissue region is modified so that the site may be easily identified after harvesting tissue molecules.
  • materials that may be attached to the sampled tissue site include, for example, a suture, a surgical clip, a biocompatible polymer that adheres to the tissue, or an RFID chip that is attached to a magnetic bead that allows easy reading and removal.
  • the probe may contain an RF emitter that is part of a RF surgical tracking system, an ultrasound emitter or reflector that is part of an intra-operative US imaging system.
  • the tracking system records location of the probe in the associated imaging system (e.g., RF, US, CT, MRI) that may be in communication with the device.
  • the operator may then identify any of the sampled tissue sites at a later time by referring to the recorded image(s) that can indicate the location of sampled sites to the operator.
  • the tissue is modified.
  • a laser source in communication with the probe may be used to ablate or coagulate a pattern into the tissue that identifies the sampled site. Any of these three approaches may be combined. For example, approach 1, 2 and 3 could be combined wherein an exogenous material is attached to the tissue site after harvesting tissue molecules and a laser patterns the exogenous tissue while an RF sensor records location of the harvest location and communicates to the imaging device.
  • the mass spectrometry comprises ambient ionization MS.
  • a probe in contact with a tissue site can be in fluid communication with the MS via a conduit.
  • conduit between the probe and tissue site is less than about 10 m, 8 m, 6 m or 4 m from MS.
  • the conduit is between about 0.5, 1.0, 1.5, 2.0, 2.5, 3.0 and 4.0 m in length.
  • subjecting the sample to mass spectrometry analysis may comprise determining a profile corresponding to the tissue site.
  • the method may additionally comprise comparing the profile to a reference profile to identify tissue sites that include diseased tissue.
  • the method also comprises resecting tissue sites that are identified to include diseased tissue.
  • the method is performed using an apparatus in accordance with any of the embodiments and aspects described above.
  • the invention provides an ex vivo method for assessing tissue samples comprising obtaining a plurality of liquid samples from a plurality of tissue sites in a subject, subjecting the plurality of liquid samples to mass spectrometry to obtain a plurality of profiles corresponding to the tissue sites, and comparing the plurality of profiles to reference profiles to identify tissue sites that include diseased tissue.
  • the liquid samples are comprised in a solvent.
  • the diseased tissues comprise cancer cells.
  • the diseased tissue sites for assessment by methods and devices of the embodiments comprise (or are suspected of comprising) cancer cells.
  • Cancer cells that may be assessed according to the embodiments include but are not limited to cells or tumor tissues from a thyroid, parathyroid, lymph node, bladder, blood, bone, bone marrow, brain, breast, colon, esophagus, gastrointestine, gum, head, kidney, liver, lung, nasopharynx, neck, ovary, pancreas, prostate, skin, stomach, testis, tongue, or uterus (or tissues surrounding such tumors).
  • the cancer may be a neoplasm, malignant; carcinoma; carcinoma, undifferentiated; giant and spindle cell carcinoma; small cell carcinoma; papillary carcinoma; squamous cell carcinoma; lymphoepithelial carcinoma; basal cell carcinoma; pilomatrix carcinoma; transitional cell carcinoma; papillary transitional cell carcinoma; adenocarcinoma; gastrinoma, malignant; cholangiocarcinoma; hepatocellular carcinoma; combined hepatocellular carcinoma and cholangiocarcinoma; trabecular adenocarcinoma; adenoid cystic carcinoma; adenocarcinoma in adenomatous polyp; adenocarcinoma, familial polyposis coli; solid carcinoma; carcinoid tumor, malignant; branchiolo-alveolar adenocarcinoma; papillary adenocarcinoma; chromophobe carcinoma; acidophil carcinoma; oxyphilic adenocarcinom
  • the cancer is a thyroid cancer, brain cancer (e.g., a glioma), a prostate cancer, a breast cancer (e.g., a triple negative breast cancer), a pancreatic cancer (e.g., a pancreatic ductal adenocarcinoma), acute myeloid leukemia (AML), melanoma, renal cell cancer or a cancer that has metastasized to a lymph node.
  • brain cancer e.g., a glioma
  • a prostate cancer e.g., a triple negative breast cancer
  • a pancreatic cancer e.g., a pancreatic ductal adenocarcinoma
  • AML acute myeloid leukemia
  • melanoma renal cell cancer or a cancer that has metastasized to a lymph node.
  • a method for characterizing a material comprising (a) applying a fixed or discrete volume of a solvent to the material; (b) collecting the applied solvent to obtain a liquid sample; and (c) subjecting the sample to mass spectrometry analysis to provide a mass spectrometry profile that characterizes the material.
  • the material is commodity product and characterizing the material comprises identifying the material.
  • the commodity product can be food, such as a meat, fish, fungus, vegetable or fruit.
  • characterizing the material comprises identifying the type of meat or fish the material is composed of.
  • the method can comprise identifying the meat as, for example, lamb, deer, moose, chicken, turkey, sheep, dog, cat, horse, pork, beef, buffalo or goat.
  • the method can be used to identify a meat as meat from a grass fed or grain fed animal.
  • the method can comprise identifying the fish as, for example, tuna, salmon, cod, trout, halibut or sea bass.
  • the method can be used to identify a fish as from a farm-raised or wild caught fish.
  • the fish can be a shell fish.
  • methods of the embodiments may be used to identify the region of origin for the food product such a fish or meat.
  • a method of characterizing a material is carried-out using an apparatus as described herein.
  • the apparatus can comprise apparatus comprising: a chamber comprising a solvent; a gas supply (e.g. a pressurized gas supply); a mass spectrometer; and a probe comprising a reservoir, a first conduit, a second conduit and a third conduit, wherein: the first conduit is in fluid communication with the chamber; the second conduit is in fluid communication with gas supply; and the third conduit is in fluid communication with the mass spectrometer.
  • a method for characterizing a material comprising (a) applying a fixed or discrete volume of a solvent to the material; (b) collecting the applied solvent to obtain a liquid sample; and (c) subjecting the sample to mass spectrometry analysis to provide a mass spectrometry profile that characterizes the material.
  • characterizing the material comprises detecting and/or quantifying the amount of a compound in the material.
  • the compound may be small molecule, such as pharmaceutical, a drug (e.g., a pain killer), a pesticide (e.g., an insecticide), a herbicide, an antibiotic or a toxin.
  • the a drug can be adderall, cocaine, codeine, morphine, marijuana, amphetamine, methamphetamine, MDMA, heroin, ketamine, lysergic acid diethylamide or oxycodone.
  • the compound can be a pesticide or herbicide such as dicamba, glyphosate, azoxystrobin or atrazine.
  • a method of characterizing a material is carried-out using an apparatus as described herein.
  • the apparatus can comprise apparatus comprising: a chamber comprising a solvent; a gas supply (e.g.
  • a pressurized gas supply a mass spectrometer
  • a probe comprising a reservoir, a first conduit, a second conduit and a third conduit, wherein: the first conduit is in fluid communication with the chamber; the second conduit is in fluid communication with gas supply; and the third conduit is in fluid communication with the mass spectrometer.
  • sample or “liquid samples” can refer to extracts from tissues or other biological specimens (e.g., extracts comprising proteins and metabolites) obtained by contacting tissue or biological specimen with a solvent according to the embodiments.
  • a sample can be an extract from a non-biological specimen, such as the surface on an object (e.g., a forensic sample).
  • essentially free in terms of a specified component, is used herein to mean that none of the specified components has been purposefully formulated into a composition and/or is present only as a contaminant or in trace amounts. The total amount of the specified component resulting from any unintended contamination of a composition is therefore well below 0.01%. Most preferred is a composition in which no amount of the specified component can be detected with standard analytical methods.
  • a” or “an” may mean one or more.
  • the words “a” or “an” when used in conjunction with the word “comprising”, the words “a” or “an” may mean one or more than one.
  • “another” or “a further” may mean at least a second or more.
  • conduit and “tube” are used interchangeably and refer to a structure that can be used to direct flow of a gas or liquid.
  • the term “about” is used to indicate that a value includes the inherent variation of error for the device, the method being employed to determine the value, or the variation that exists among the study subjects.
  • FIG. 1 Representative schematic of a mass spectroscopy probe for minimally invasive surgery.
  • FIG. 2 Multilumen tubing for use with the mass spectroscopy probe for minimally invasive surgery.
  • FIG. 3 A cannula and trocar needle for housing and inserting the mass spectrometry probe for minimally invasive surgery.
  • FIG. 4 Representative schematic of a mass spectrometry probe for minimally invasive surgery. This embodiment includes a shutter for occluding the probe.
  • FIG. 5 Mass spectra of mouse brains tissue section from the minimally invasive mass spectrometry probe using Q Exactive Orbitrap Mass Spectrometer. PTFE tubing of 1.5 meters was used with an inner diameter of 2 mm and outer diameter of 4 mm.
  • FIG. 6 Mass spectra of mouse brains tissue section from the minimally invasive mass spectrometry probe using Q Exactive Orbitrap Mass Spectrometer. PTFE tubing of 3.5 meters was used with an inner diameter of 2 mm and outer diameter of 4 mm.
  • FIG. 7 Mass spectra of mouse brains tissue section from the minimally invasive mass spectrometry probe using Q Exactive Orbitrap Mass Spectrometer. PTFE tubing of 4.5 meters was used with an inner diameter of 2 mm and outer diameter of 4 mm.
  • FIG. 8 Mass spectra of mouse brain tissue section from the minimally invasive mass spectrometry probe using Q Exactive Orbitrap Mass Spectrometer.
  • FIG. 9 Representative schematice of a mass spectrometry probe for minimally invasive surgery. Depicted on the lower left is the multichannel probe tip.
  • FIG. 10 Simulated laparoscopic surgery shown from a laparoscopic optical camera on a simulated uterus. Shown on the right are forceps holding the minimally invasive mass spectrometry probe.
  • FIG. 11 Mass spectra generated from a 16 ⁇ m mouse brain section using 4.5 meter long tubing compared to the water background.
  • FIG. 12 Mass spectra generated with the minimally invasive mass spectrometry probe using Q Exactive Orbitrap Mass Spectrometer and conduits of 1.5-4.0 mm diameter.
  • FIG. 13 Depiction of the mechanics of a balloon shutter for use with the minimally invasive mass spectrometry probe.
  • FIG.14 Mass spectra of human lung tissue section from the minimally invasive mass spectrometry probe using Q Exactive Orbitrap Mass Spectrometer.
  • FIG. 15 Diagram of washing chamber for minimally invasive mass spectrometry probe.
  • FIGS. 16A-16D Schematic representation of the laparoscopic MasSpec Pen system being used in a (a) manual laparoscopic MIS procedure and (b) robotic assisted MIS.
  • the pen tip was designed with a grasping fin to allow manipulation and application of the MasSpec Pen using forceps or other graspers.
  • FIGS. 17A-17C Comparison between designs and performance of the handheld and laparoscopic MasSpec Pen.
  • the handheld MasSpec Pen contains a PDMS tip and three PTFE conduits, which provide incoming water (1) and gas (2) to the tip, and an outgoing conduit (3) for the water droplet to the mass spectrometer.
  • the pen tip holds a water droplet within the reservoir, which contacts tissue for analysis.
  • the laparoscopic MasSpec Pen PDMS tip is grafted with two micro-PTFE tubes, one for the incoming water (1), and another for incoming gas (2). The proximal end of the pen tip was then connected to a larger PTFE conduit, which functions as the outgoing water conduit (3).
  • FIGS. 19A-19B An automated system was developed for automatic mass spectrometry data acquisition, statistical analysis, and communication of results.
  • a foot pedal is used to trigger the analysis workflow through communication with an chicken microcontroller, which then activates water droplet deposition by triggering the syringe pump. In the GUI, the user selects which type of tissue is being evaluated prior to usage, so that the software selects the proper statistical classifier, providing a predictive diagnosis with the associated cancer probability.
  • the laparoscopic MasSpec Pen platform was tested using a mannequin through an 8 mm cannula. Laparoscopic forceps were used to manipulate the MasSpec Pen, while a video camera was employed to transmit an image and/or video of the organs inside the abdomen and guide the operator during the procedure.
  • FIGS. 20A-20C (a-c) Representative mass spectra obtained from mouse brain tissue sections with laparoscopic MasSpec Pen at reservoir diameters of 1.5, 2.7, and 4.0 mm and a 4.5 meter tubing length.
  • FIG. 21 Representative mass spectra obtained with the laparoscopic MasSpec Pen (2.7 mm reservoir diameter and a 4.5 meter tubing length) of a human normal and a cancerous ovarian tissues.
  • FIG. 22 Representative mass spectra obtained with the MasSpec Pen from samples of beef, lamb, chicken and pork using CAN:DMF 1:1 as the solvent. Results show that the spectra obtained using the MasSpec Pen were able to assess the source of the meat with a high level of accuracy.
  • FIG. 23 Representative mass spectra obtained with the MasSpec Pen from samples of grass-fed versus grain-fed beef (using CAN:DMF 1:1 as the solvent). Results show that the spectra obtained using the MasSpec Pen were able determine whether the meat was sourced from a grass-fed or grain-fed animal with a high level of accuracy.
  • FIG. 24 Representative mass spectra obtained with the MasSpec Pen from samples of beef, lamb, chicken and pork using water as the solvent. Results show that the spectra obtained using the MasSpec Pen were able to assess the source of the meat with a high level of accuracy even when using water as the only solvent.
  • FIG. 25 Representative mass spectra obtained with the MasSpec Pen from samples of fish, including Atlantic salmon, sockeye salmon, steelhead trout, cod loin or halibut (using ACN:DMF (1:1) as a solvent). Results show that the spectra obtained using the MasSpec Pen were able to assess the source of the fish with a high level of accuracy.
  • FIG. 26 Representative mass spectra obtained with the MasSpec Pen from samples including amounts of illicit drugs, cocaine and amphetamine. Results show that the spectra obtained using the MasSpec Pen were able to detect the drugs with a high degree of sensitivity and quantify the amount of drug in the sample.
  • FIG. 27 Representative mass spectra obtained with the MasSpec Pen from samples including amounts of oxycodone. Results show that the spectra obtained using the MasSpec Pen were able to detect and quantify the amount of oxycodone in the sample.
  • FIG. 28 Representative mass spectra (and a comparative chromatograph) obtained with the MasSpec Pen from samples including the pesticide azoxystrobin. Results show that the MasSpec Pen analysis was able to detect and quantify the amount of pesticide in the sample.
  • FIG. 29 Representative mass spectra (and a comparative chromatograph) obtained with the MasSpec Pen from samples including the pesticide atrazine. Results show that the MasSpec Pen analysis was able to detect and quantify the amount of pesticide in the sample.
  • FIG. 30 Representative mass spectra obtained with the MasSpec Pen from grapes. Results show that the MasSpec Pen analysis was able to produce a spectrum that could be used to characterize the sample.
  • the instant application provides methods and devices for minimally invasive molecular assessment of samples, such as tissue samples.
  • the methods can be used to assess multiple tissue sites during an operation (or biopsy) of the tissue. This feature allows for accurate identification of diseased tissues (e.g., tissue sites retaining cancer cells) in “real-time” allowing surgeons to more accurately address only the diseased tissue relative to surrounding normal tissues.
  • the methods disclosed here can involve delivery of a fixed or discrete volume of solvent to a tissue site, followed by collection of a liquid sample from the site and analysis of the liquid sample by mass spectrometry.
  • solvent is applied as discrete droplets and at low pressure.
  • the methods detailed herein can be used to collect and analyze samples from a wide range of sources.
  • the methods can be used to assess surgical, forensic, agriculture, pharmaceutical, and/or oil/petroleum samples.
  • the materials (PDMS and PTFE) and solvent (e.g., water only solvents) used in the devices of the embodiments are biologically compatible, such that they can be used in surgery in for real-time analysis. Furthermore, because the devices can be very compact, it can be hand-held and used in used in minimally invasive surgical procedures, or non-surgical procedures.
  • the present invention provides devices of extended length and increased compactness for delivery of fixed or discrete volumes of solvents to tissues for use in minimally invasive surgeries.
  • these methods can be encapsulated in a variety of form factors such as a conduit, ranging from 0.5 mm to 10.0 mm inner diameter (e.g., with an inner diameter of between about 1.0 and 5.0; 1.0 and 10.0; 2.0 and 8.0; or 5.0 and 10.0 mm).
  • the site of delivery of a fixed or discrete volume of solvent, followed by collection of a liquid sample may be inside the body, such as a surgical site.
  • two smaller conduits may be inserted into a third, larger, conduit to create a multi-lumen catheter.
  • the multi-lumen catheter can have 2, 3, 4, 5, 6 or more luminal spaces with each having an internal diameter of, e.g., 0.05 to 5.0 mm; 0.1 to 5.0 mm; 0.25 to 3.0 mm; or 0.5 mm to 10.0 mm.
  • the multi-lumen catheter may be attached to a mass spectrometry device for analysis of sample tissues inside the body during surgery, while avoiding unnecessary damage to surrounding tissues.
  • the device may be used through cannulas or catheters in minimally invasive surgical or endoscopy procedures, or may be used in non-surgical procedures through needle guides or biopsy guides.
  • the present invention can be integrated into a robotic surgical system allowing several regions of the human body cavity to be quickly sampled and analyzed.
  • the device be used to analyze tissues using a database of molecular signatures and machine learning algorithms, allowing diagnosis in real time for each sampled region.
  • the present invention may be used in a wide variety of oncological and other surgical interventions, such as endometriosis, for which real time characterization and diagnosis of tissues are needed.
  • the present disclosure provides an attachment to the probe, for fine manipulation of the probe during minimally or non-invasive procedures.
  • the attachment to the probe may be a fin.
  • such a fin may be composed of the same material as the probe.
  • the fin is made of PDMS.
  • a fin can, in some aspects, be formed by an injection molding process or it may be 3D printed.
  • the present invention may further comprise a device for grasping the probe, external to the probe, in order to manipulate the probe during laparoscopic procedures. The grasping device may be used to hold, rotate, or move the probe, or may grasp the fin attached to the probe, in order to move or rotate the probe.
  • the present invention maintains a reservoir using a multi-lumen catheter with recessed ports for depositing water and nitrogen gas during laparoscopic surgical procedures.
  • a multi-lumen catheter may be formed, for example, using a multi-lumen extrusion as is well known in the art. These catheters may be utilized in any cannula. The most commonly used cannulas are of 5 mm and 10 mm diameters, and are typically used for laparoscopic surgeries.
  • multi-lumen tubing may be used with an external vacuum source in order to attach the probe to the tissue surface while analyzing.
  • the present invention provides a shutter system that occludes the orifice of the minimally invasive surgical device.
  • this shutter system may be a catheter balloon that is integrated within the device or added separately to the device.
  • the shutter, or balloon may close the probe tip, preventing unwanted biological material from entering the device, including the lumens and tubing, upon insertion of the catheter into the patient.
  • the shutter or balloon may disallow endogenous biological fluids from entering the mass spectrometer after analysis has been initiated, thus preventing contamination of the results. Finally, closing of the shutter or balloon may prevent excess nitrogen gas and water from entering the body.
  • the present invention may be used with robotic manipulation.
  • the technologies of the present invention may integrate in modern surgical theaters through an accessory port, or via a robotic arm. These devices may be integrated into robotic systems such as the Intuitive Surgical da Vinci robotic surgical system.
  • a device of the present invention may have its own dedicated arm in a robotic system, or be handled by robotic graspers by incorporating a “fin” onto the probe. Smaller and larger diameters can also be used to be coupled to any existing catheters, cannulas and also needle/biopsy guides.
  • a tracking probe can be integrated with this device in order to display and record where the tissue sample has been analyzed to better assist the surgeon in localizing the sampling points both intraoperatively or otherwise.
  • an ultrasound emitter on the device may be utilized to display the probe when sampling.
  • the probe may be integrated with a tracking device based on radio frequency technology, such as the Biosense Webster Carto system. In that case, the probe may display the device/sampling location on any of a variety of imaging modalities, such as intraoperative UltraSound (US)/Computed Tomogrpahy (CT)/Magnetic Resonance Imaging (MRI)/Optical Coherence Tomography (OCT).
  • US intraoperative UltraSound
  • CT Computed Tomogrpahy
  • MRI Magnetic Resonance Imaging
  • OCT Optical Coherence Tomography
  • fluorescent imaging and molecular dyes may be used to track the analyzed areas and charted to provide 2-dimensional or 3-dimensional spatial imaging. More simply, the probe tip may be coated with a surgical dye which is then stamped on the tissue to track the region analyzed. Yet another tracking approach is to integrate an RF emitter into the probe so that the spatial location may be tracked.
  • the probe of the present invention may be used to assist surgeons and medical professionals during minimally invasive surgical interventions by providing comprehensive and definitive diagnostic molecular information in vivo and in real time, without necessarily causing damage or alteration to the patient's native living tissues.
  • the handheld MasSpec Pen has demonstrated a capacity to do this during non-laparoscopic/endoscopic surgical procedures (U.S. patent application Ser. No. 15/692,167 incorporated herein by reference, in its entirety).
  • the present invention is suitable for ex vivo analysis of tissues (fresh, frozen, sections, biopsies) or other clinical specimens that might be examined by a pathologist, and may be used for chemical analysis of any given sample for which direct analysis is desired in confined and spatially limited domains (animals, plants, explosives, drugs, etc).
  • tissue types may be analyzed as well, including but not limited to, breast, kidney, lymph node, thyroid, ovary, pancreatic and brain tissues.
  • the probe of the present invention may be used in conjunction with surgical instruments for the treatment of a disease.
  • surgical instruments may be used to excise or ablate cells or tissues, including, but not limited to, laser ablation tools, tools for cauterization or electrocauterization, or tools for the manual dissection of tissue such as a scalpel.
  • a device of the embodiments further comprises a shutter system that can occlude the orifice, and creates a separation between the reservoir and the tissue.
  • the shutter system can activate after the droplet rests for 3 seconds and before the droplet is transported to the mass spectrometer.
  • the shutter can be an iris diaphragm, a mechanical closure, gate, or tapenade.
  • An additional design for the shutter is a balloon mechanism, which seals the exterior of the device from the tissue. The balloon can be positions on the distal end of the conduit, e.g., perpendicular to the pen or probe.
  • the balloon When activated, the balloon expands and fills up the reservoir towards the direction of the tissue. This accomplishes at least 3 things: first it gently lifts the pen tip off of the tissue using the inflated balloon, insuring that there is no damage to the tissue. This is to ensure that the probe remains nondestructive and biocompatible in case the analyzed tissue is determined to be ‘normal’. Secondly, it seals the solvent droplet that is inside the reservoir and prevents leakage or absorbance of lipids after the sampling window. Thirdly, it creates a seal at the end of the conduit, which will allow for more effective transfer of the droplet to the mass spectrometer.
  • a reservoir includes using a multi-lumen catheter, e.g., with recessed ports for depositing water and nitrogen gas.
  • the reservoir also retains the water during the extraction period.
  • a multi-lumen catheter can be formed for example using a multi-lumen extrusion as is well known in the art. It has been demonstrated that these catheters can be utilized in any cannula, most commonly 5 mm and 10 mm diameters, for laparoscopic surgeries. This technology is compatible with robotic manipulation such as the Intuitive Surgical da Vinci robotic surgical system.
  • the Laparoscopic/Endoscopic probes will easily integrate in current surgical theaters through an accessory port or via a robotic arm. Smaller and larger diameters can also be used to be coupled to any existing catheters, cannulas and also needle/biopsy guides.
  • a probe system of the embodiments can incorporate additional valves.
  • micro-solenoid valves can be located at each conduit, e.g., at the distal end of the sampling probe. These will be individually controlled by an arduino, microcontroller, or signal. In some cases the value operation is automated. In other cases it can be manually controlled.
  • valves are positioned in the inner wall of the solvent conduit sealing the conduits. Thus, by using such values, only two or even one conduit can be used in the sampling operation. For example, a delivering solvent conduit and a return conduit to transfer the droplet to the mass spectrometer. Additional micro-solenoids could be implanted to have more control. For example, three or four micro-solenoids can be into the probes of the embodiments.
  • Laparoscopic/Endoscopic probes of the embodiments are a ‘fin’ that can be grasped by forceps, robotic tools, or laparoscopic graspers. This will allow the probe to be used in a variety of modalities without sacrificing resolution or sensitivity.
  • the fin itself is a gradual sloped protrusion from the exterior of the conduit running parallel to said conduit. It is textured to provide extra traction for the grasping mechanism.
  • a tracking probe can be integrated with this device in order to display and record where the tissue sample has been analyzed to better assist the surgeon in localizing the sampling points both intraoperatively or otherwise.
  • an ultrasound emitter on the device may be utilized to display the probe when sampling.
  • the probe can be integrated with a tracking device based on radio frequency technology, such as the e.g., Biosense Webster Carto system. With this approach, the probe displays the device/sampling location on any various imaging modalities like intraoperative UltraSound (US)/Computed Tomography (CT)/Magnetic Resonance Imaging (MRI)/Optical Coherence Tomography (OCT).
  • US intraoperative UltraSound
  • CT Computed Tomography
  • MRI Magnetic Resonance Imaging
  • OCT Optical Coherence Tomography
  • tissue sites that are assessed by a probe of the embodiments can be marked.
  • a dye that is up-taken by cancerous cells and normal cells which will mark where the probe has been placed.
  • a chemical dye can be delivered using an additional conduit in the catheter or by using a multilumen catheter.
  • An alternative delivery of a tracking dye is to dissolve it in the solvent that we use to analyze the tissue.
  • one advantage of using a dye within the solvent is that it will directly correlate with where the tissue sample was taken, instead of the peripheral region.
  • the chemical dye would be present in the mass spectra and would have to be distinguished from biomolecules in a sample.
  • the dye may be visible (e.g., in white operating room light).
  • the dye may be a fluorescent dye.
  • the pen tip can be coated with a surgical dye, which is then stamped on the tissue to track the region analyzed.
  • a tracking approach can be used to virtually map the tissues sites analyzed.
  • a RF emitter can be integrated into a probe so that the spatial location may be tracked.
  • dyes or probe tracking
  • tissues analyzed can be charted to provide 2 dimensional and 3 dimensional spatial imaging.
  • a probe system can include a filter.
  • a filter can prevent biological tissue from going into the conduits.
  • a filter mesh system can be incorporated within the device to prevent smaller bodies of tissue, protein aggregates, or coagulated cell clusters from entering. This mesh could be placed at the opening and have contact with the tissue, or be positioned higher up within the probe, such that no tissue contact occurs.
  • a filter mesh comprises average apature sizes of less than about 1.0, 0.5, 0.25 or 0.1 mm. Since solid matter can damage a mass spectrometer, such a filter system can increase instrument lifespan with out negatively effecting signal detected.
  • an endoscopic/laparoscopic probe of the embodiments is integrated with a microcontroller, user interface, and/or associated hardware that will operate with appropriate software.
  • a light such as a LED will be incorporated to provide visual feed back to the user, for example, to indicate that the probe is ready for sampling, in the process of doing so, or needs to be replaced/repaired.
  • Acoustic feedback can also be used, for instance, to let the user know what step of the process the device is in (e.g., since physical cues may be unavailable laparoscopically).
  • a user interface system can also be integrated with the device, such as in a foot pedal and buttons on the housing of the probe.
  • the present disclosure provides methods of determining the presence of diseased tissue (e.g., tumor tissue) or detecting a molecular signature of a biological specimen by identifying specific patterns of a mass spectrometry profile.
  • Biological specimens for analysis can be from animals, plants or any material (living or non-living) that has been in contact with biological molecules or organisms.
  • a biological specimen can be samples in vivo (e.g. during surgery) or ex vivo.
  • a profile obtained by the methods of the embodiments can correspond to, for example, proteins, metabolites, or lipids from analyzed biological specimens or tissue sites. These patterns may be determined by measuring the presence of specific ions using mass spectrometry.
  • Some non-limiting examples of ionizations methods that can be coupled to this device include chemical ionization, laser ionization, atmospheric-pressure chemical ionization, electron ionization, fast atom bombardment, electrospray ionization, thermal ionization.
  • Additional ionization methods include inductively coupled plasma sources, photoionization, glow discharge, field desorption, thermospray, desorption/ionization on silicon, direct analysis in real time, secondary ion mass spectroscopy, spark ionization, and thermal ionization.
  • the present methods may be applied or coupled to an ambient ionization source or method for obtaining the mass spectral data such as extraction ambient ionization source.
  • Extraction ambient ionization sources are methods with, in this case, liquid extraction processes dynamically followed by ionization.
  • extraction ambient ionization sources include air flow-assisted desorption electrospray ionization (AFADESI), direct analysis in real time (DART), desorption electrospray ionization (DESI), desorption ionization by charge exchange (DICE), electrode-assisted desorption electrospray ionization (EADESI), electrospray laser desorption ionization (ELDI), electrostatic spray ionization (ESTASI), Jet desorption electrospray ionization (JeDI), laser assisted desorption electrospray ionization (LADESI), laser desorption electrospray ionization (LDESI), matrix-assisted laser desorption electrospray ionization (MALDESI), nanospray desorption electrospray ionization (nano-DESI), or transmission mode desorption electrospray ionization (TM-DESI).
  • AFADESI air flow-assisted desorption electrospray ionization
  • DART direct analysis
  • ionization efficiency can be optimized by modifying the collection or solvent conditions such as the solvent components, the pH, the gas flow rates, the applied voltage, and other aspects which affect ionization of the sample solution.
  • the present methods contemplate the use of a solvent or solution which is compatible with human issue.
  • solvent which may be used as the ionization solvent include water, ethanol, methanol, acetonitrile, dimethylformamide, an acid, or a mixture thereof.
  • the method contemplates a mixture of acetonitrile and dimethylformamide.
  • the amounts of acetonitrile and dimethylformamide may be varied to enhance the extraction of the analytes from the sample as well as increase the ionization and volatility of the sample.
  • the composition contains from about 5:1 (v/v) dimethylformamide:acetonitrile to about 1:5 (v/v) dimethylformamide:acetonitrile such as 1:1 (v/v) dimethylformamide:acetonitrile.
  • the solvent for use according to the embodiments is a pharmaceutically acceptable solvent, such as sterile water or a buffered aqueous solution.
  • the system developed consists of three main parts: 1) a syringe pump that is programmed to deliver a discrete solvent volume using a controlled flow rate; 2) tubing systems integrated to two-way pinch valves for controlled solvent and gas transport; 3) a probe tip which is used for direct sampling of biological tissues.
  • the tubing systems and probe tip are also integrated into a minimally invasive surgical device such as a cannula or catheter for use in laparoscopic or endoscopic surgeries.
  • Several iterations of the system were explored and optimized with the ultimate goal of minimizing tissue damage, maximizing tissue-analyte extraction, and maximizing solvent transmission to the mass spectrometer.
  • FIG. 1 shows a schematic figure of one example of a minimally invasive apparatus for analyzing biological tissue.
  • the syringe pump feeds solvent and gas into the minimally invasive probe via micro-PTFE tubing.
  • the probe maintains contact with the sample, retains solvent during interaction with the tissue.
  • the tip was manufactured using 3D-printing and is made of biologically compatible polydimethylsiloxane (PDMS).
  • PDMS biologically compatible polydimethylsiloxane
  • the probe has three main ports: one for the incoming tubing system, a central port for gas delivery, and a third for the outgoing tubing system. All ports come in junction at a small reservoir where the droplet is retained and exposed to the tissue sample for a controlled amount of time, allowing for efficient extraction of molecules. The size of the reservoir determines the spatial resolution of the device. A solvent volume of 10 ⁇ L is exposed to the tissue sample.
  • FIG. 2 shows the three conduit tubes.
  • the three conduit tubes used are made of polytetrafluoroethylene (PTFE), which is also biologically compatible.
  • PTFE polytetrafluoroethylene
  • the tube from the syringe pump is used to deliver solvent from syringe pump to the probe tip, while the other micro-PTFE tube is used to deliver an inert gas (N 2 or CO 2 ) to the probe tip.
  • the gas serves three main purposes: 1) tissue drying prior to analysis; 2) prevent solvent gap due to the mass spectrometer's vacuum when the reservoir is closed by contacting the tissue specimen; 2) assist solvent transport from tissue to the mass spectrometer through the wider PTFE tubing.
  • FIG. 9 shows a schematic of the minimally invasive probe which includes a diagram of the tip of the probe, including the tree conduit tubes and the reservoir at the base (labelled 4).
  • FIG. 3 shows two of the possible devices to house the minimally invasive probe.
  • the cannula shown has the gas and solvent tubing entering the top, as well as the tubing to the mass spectrometer.
  • the probe is shown emerging from the bottom of the cannula. The probe may also be introduced into the body cavity using a trocar needle.
  • FIG. 9 shows a schematic of the minimally invasive probe which includes a diagram of the tip of the probe, including the tree conduit tubes and the reservoir at the base (labelled 4).
  • FIG. 3 shows two of the possible devices to house the minimally invasive probe.
  • the cannula shown has the gas and solvent tubing entering the top, as well as the tubing to the mass spectrometer.
  • the probe is shown emerging from the bottom of the cannula.
  • the probe may also be introduced into the body cavity using
  • FIG. 10 depicts a simulated laparoscopic uterine surgery, and shows that the minimally invasive probe may be controlled by forceps.
  • a shutter system that occludes the orifice of the minimally invasive probe may be employed as shown in FIG. 4 .
  • One option for the shutter is to use a catheter balloon which may close the probe tip, a diagram of which is shown in FIG. 13 , preventing unwanted biological material from entering the device, including the lumens and tubing, upon insertion of the catheter into the patient.
  • the shutter may disallow endogenous biological fluids from entering the mass spectrometer after analysis has been initiated, thus preventing contamination of the results. Closing of the shutter can also prevent excess nitrogen gas and water from entering the body.
  • the minimally invasive mass spectrometry probe may also include a vacuum tube separate from the sample vacuum above. The purpose of this second vacuum tube is to gently secure, or latch, the tip of the probe onto the tissue during analysis.
  • the time events involved in the device operation are automated and precisely controlled by software that communicates with an Engineering system and two two-way pinch valves. All pinch valves are closed until the process is initiated when, under 300 ⁇ L/min, a pulse is sent to the pump to infuse the solvent for two seconds and stop, generating a 10 ⁇ L droplet filling in the minimally invasive probe reservoir.
  • the gas and mass spectrometer tubes are closed at pinch valves, allowing the solvent in the reservoir to interact with the tissue for three seconds to extract the molecules.
  • the pinch valves controlling the gas and mass spectrometer tubes are opened simultaneously, allowing the droplet to transfer to the mass spectrometer for ionization and molecular analysis.
  • a pulse is sent to the pump to infuse the solvent for another 12 seconds and stop, to completely drive all the extracted molecules into the mass spectrometer.
  • the gas and mass spectrometer tubes are left open for another 20 seconds to allow all the solvent in the mass spectrometer tube to go into the mass spectrometer.
  • the total analyzing time is 37 seconds.
  • the probe may be washed between analyses in a variety of methods.
  • the tip of the probe is wiped with sterile water.
  • An additional design that can facilitate the washing step is a retractable design that will wash the exterior of the probe without having to remove the device from the patient ( FIG. 15 ).
  • the design consists of a chamber with valves located at the openings to maintain a water and gas seal.
  • a longer tube that contains the probe tip, water, and gas conduits will transect only the top valve when the tip is located in the washing chamber, but will pass through both valves when the tip is deployed into the patient environment. After the probe tip, tubing, or both have become contaminated during the surgery process, the probe will withdraw into the washing chamber.
  • Water tubes can be located inside the washing chamber and point upwards providing a strong jet of cleaning solvent. Two positions of vacuum tubing will be located above the first and second valve to remove dirtied solvent. The vacuum tube placed above the first valve is an emergency tube in case any water breaks the first valve barrier. The entire system will fit smoothly inside of a trocar, and the deployable probe will be located inside of this system. The vacuums located inside the probe will also operate during this cleaning process, which will flush the tubing until clean.
  • the system described herein operates by directly connecting the transfer tube to the mass spectrometer inlet for transporting the analyte-containing solvents to the mass spectrometer for molecular analysis.
  • This set up greatly simplifies operational details and precludes the use of ionization sources.
  • the solvent is then transported to the mass spectrometer and directly infused without the need of an additional ionization source. Since the system is fully automated so that each 10 ⁇ L solvent droplet is delivered separately to the inlet, the mass spectrometer operates without any impact on its performance. Rich molecular information is obtained in this manner, similar to what is observed from other solvent-extraction ambient ionization techniques such as desorption electrospray ionization.
  • the ionization mechanism may be similar to inlet ionization.
  • the ionization occurs in the inlet pressure drop region between atmosphere and vacuum. Because of the nature of minimally invasive surgical techniques, the diameter of tubing, and length of tubing is of critical importance. A variety of tube lengths were tested for the delivery of solvent to the mass spectrometer, as seen in FIGS. 5-8 ).
  • FIGS. 5-8 show the total ion chromatograms obtained from mouse brain sections during the total analysis period while using tubing lengths of 1.5 meters up to 4.5 meters. Rich molecular profiles were observed in all cases. At a tube length of 4.5 meters the molecular profile is easily established over the background signal of the water ( FIG. 11 ).
  • FIG. 12 shows total ion chromatograms obtained using conduit sizes from 1.5 mm to 4.0 mm. Again, rich molecular profiles were observed with each conduit size.
  • human lung tissue was analyzed ( FIG. 14 ), and generated a robust molecular profile.
  • the molecular profiles generated by the minimally invasive mass spectrometry probe can also be used for tissue typing.
  • a series of tissue samples were evaluated with the minimally invasive mass spectrometry probe and were able to be identified with an overall accuracy of 98.55% (Table 1).
  • the system was able to identify lymph, breast, and lung tissues with 100% accuracy, thyroid and parathyroid with between 97% and 99% accuracy, ovarian with 95.35% accuracy, and pancreas tissue with 83.33% accuracy. These tissue typing results were generated from selected features of the mass spectrometry profiles shown in Table 2.
  • Thyroid Lymph Parathyroid Breast Lung Ovarian Pancreas m/z ⁇ 0.25915 ⁇ 1.37199 0.833471 ⁇ 0.44036 ⁇ 0.34999 2.269018 ⁇ 0.68101 125.01 0 0 0 0 0 0.097137 0 130.06 0 0 0.008242 0 0 0 0 0 146.05 0 0 ⁇ 0.00177 0 0 0 0 147.69 0 0 0.28651 0 0 0 0 148.95 0 0 0 0 0 0.025703 0 183.96 0 0 0 0 0 0 0.014118 0 191.02 0 0 0 0 0 ⁇ 0.01003 0 194.99 0 0 0 0 0 0.00062 0 0 200.17 0 ⁇ 0.00053 0 0 0 0 0 0 205.46 0 0 0 0 0
  • the minimally invasive mass spectrometry probe can be used to differentiate between normal and cancerous tissues.
  • the system predicted normal tissues with greater than 89% accuracy, and cancer tissues with greater than 91% accuracy as seen in Table 3.
  • Mass Spectrometer Q Exactive Hybrid Quadrupole-Orbitrap mass spectrometer (Thermo Scientific, San Jose, Calif.) was used. Full-scan was carried out at the range of m/z 500-1800, and the other mass spectrometric parameters were listed as follows: resolving power 140,000, micro scan 2, maximum injection time 300 ms, capillary temperature 350° C. and S-lens RF level 100.
  • Wild-type mouse brains were purchased from Bioreclamation IVT.
  • 62 frozen human tissue specimens including breast, thyroid, lymph node, ovarian, and kidney were obtained from Cooperative Human Tissue Network and Baylor College Tissue Bank. Samples were stored in a ⁇ 80° C. freezer. Tissue slides were sectioned at 16 ⁇ m using a CryoStar NX50 cryostat. Frozen tissue specimen were thawed under room temperature before use.
  • IBM SPSS Statistics 22.0 (IBM Corporation, Armonk, N.Y., USA) was used to perform principal component analysis (PCA) to reveal patterns in the data. The analysis was performed directly using the raw data. The 10 peaks of the top relative intensities in the m/z range of 700-900 were used for PCA. Typically, the first three components, which all encompassed more than 85% of the total variance, are used in the present results.
  • the system has a high potential to be used in laparoscopic and endoscopic surgeries for real-time analysis. More than that, due to the small dimension of the device, it can be integrated to a robotic surgical system, such as the Da Vinci surgical system, through an accessory port or one of its robotic arms.
  • a robotic surgical system such as the Da Vinci surgical system
  • Several regions of the human body cavity can be quickly sampled during surgery with or without wash/flush steps in between each analysis, and analyzed by using a database of molecular signatures and machine learning algorithms. Therefore, the diagnosing results may be provided in real time for each sampled region.
  • This system can be broadly used in a wide variety of oncological and other surgical interventions (such as endometriosis) for which real-time characterization and diagnosis of tissues are needed.
  • a laparoscopic MasSpec Pen platform was developed, which may be used in manual or robotically controlled MIS procedures ( FIGS. 16A and 16B ).
  • the laparoscopic MasSpec Pen platform was developed with emphasis on three main design features: 1) adherence to dimensions and material specifications necessary for use in the laparoscopic environment; 2) similar performance specification to the handheld MasSpec Pen to ensure compatibility with the previously generated statistical models; and 3) integration to an automated software and graphical user interface for real time data analysis and statistical classification.
  • the laparoscopic MasSpec Pen was engineered with the specifications needed to function in MIS. Design modifications allowed introduction of the MasSpec Pen through the cannula of a laparoscopic trocar, or through the open ports of robotic systems (commonly of 5 mm, 8 mm, or 12 mm in diameter), while maintaining similar operation to the handheld MasSpec Pen.
  • the handheld MasSpec Pen has a diameter of 10 mm, which was dictated by the diameter of the 3D printed polydimethylsiloxane (PDMS) pen tip.
  • the tip of the handheld MasSpec Pen was designed with three conduits (incoming water, incoming gas, and outgoing water), which are in fluid communication with an open reservoir that positions the water droplet for contact with tissue surface ( FIG. 17A ).
  • PTFE micro-polytetrafluoroethylene
  • the reservoir was designed with three diameters of 1.5 mm, 2.7 mm, and 4.0 mm to display a range of capabilities. Although reservoir diameters below 1.5 mm could be manufactured via micromolding, these were not tested due to limitations in manufacturing capabilities. Further, current recommended cancer-free margins for solid cancer excision are often larger than 1.5 mm—such as 3 mm for basal cell carcinoma, 2 mm for breast cancer, and 5 cm for gastric cancer.
  • a grasping fin was incorporated on the pen tip to provide an anchor point for a laparoscopic tool, such as forceps or a robotic arm ( FIG. 16C ).
  • a laparoscopic tool such as forceps or a robotic arm
  • organ access is dictated by trocar placement.
  • One benefit of the laparoscopic MasSpec Pen is flexibility and light weight of the polymer-based tubing system. These features allow the device to be easily manipulated through a trocar in the x, y, and z directions given the cannula's placement in reference to an organ of interest.
  • a 3 mm in length fin was incorporated into the 3D printed molds unilaterally at the proximal end of the pen tip to avoid increasing the diameter of the device.
  • the total diameter of the laparoscopic MasSpec Pen including the fin was 7.5 mm for the 1.5 and 2.7 mm reservoir diameter tips, and 9.5 mm for the 4.0 mm reservoir diameter tip; all compatible for use through common sized trocars.
  • FIGS. 18A-C show the mass spectra obtained from serial sections of mouse brain tissue analyzed with the 2.7 mm laparoscopic MasSpec Pen at 1.5 m, 3.0 m and 4.5 m tubing lengths.
  • a 2.7 mm reservoir diameter and 4.5 m tubing length were chosen for the remaining experiments performed with the laparoscopic MasSpec Pen. Using these parameters, an overall measurement time of ⁇ 20 seconds/spot was achieved, which includes the time employed for tissue sampling (3 seconds), droplet transport (7 seconds), and droplet ionization and analysis ( ⁇ 10 seconds).
  • GUI graphical user interface
  • a foot pedal is used to trigger the analysis workflow.
  • the system was further refined so that the foot pedal also triggers the lab-built software ( FIG. 19A ).
  • the user selects which type of tissue is being evaluated in the GUI prior to tissue analysis, so that the software properly selects the corresponding statistical model for data analysis.
  • a syringe pump is triggered so that a discrete water droplet is formed in the pen tip, where it interacts with the tissue for 3 seconds.
  • the droplet enriched with extracted bio-molecular species is transported to the Orbitrap mass spectrometer through a PTFE tube for ionization and mass analysis, as previously explained.
  • the mass spectra data is continuously recorded and read by the software program.
  • the three mass spectra with the highest intensity for selected ions are averaged and pre-processed for statistical analysis. Prediction is then performed using the statistical models previously built by the Lasso method using data acquired from histologically validated tissues and the probability of the tissue being cancer is reported in the GUI.
  • HGSC high grade serous carcinoma
  • samples with a predictive probability greater than 0.51 were as “cancer”, while samples with predictive probabilities lower than 0.51 were called “normal”.
  • 100% sensitivity for cancer diagnosis was achieved, as all of the regions of the five cancer samples analyzed were classified as cancer.
  • One of the seven normal tissue samples (ON_164b) was misclassified as cancer in both regions analyzed, while one of the four regions analyzed of sample ON_135a was classified as cancer, yielding 80% selectivity. Overall, an 87.5% agreement between the predictive and pathologic diagnoses was achieved.
  • the laparoscopic MasSpec Pen was tested using a laparoscopic simulation mannequin.
  • the laparoscopic MasSpec Pen was inserted into the mannequin through an 8 mm cannula.
  • laparoscopic forceps were used to manipulate the MasSpec Pen, while a video camera was employed to transmit an image and/or video of the organs inside the abdomen and guide placement of the laparoscopic MasSpec pen during the procedure ( FIG. 19B ).
  • Normal and cancer human ovarian samples were placed on top of a mimic organ and accessed through the laparoscopic incisions inside the mannequin, and then analyzed using the laparoscopic equipment. Forceps were used to grasp the engineered fin and correctly guide the pen to the tissue surface for analysis.
  • the laparoscopic MasSpec Pen is an automated device that provides near real time diagnostic information for MIS.
  • the unique design and features of laparoscopic MasSpec Pen described meet many of the requirements needed for manual and robotic MIS.
  • similar molecular patterns were obtained from mouse brain tissue sections.
  • Different pen tip diameters and tube lengths were also tested for various clinical needs.
  • a customized lab-built software was developed, providing a fully automated workflow for tissue analysis and diagnostic feedback. This technology may be a complementary tool for MIS, which could expedite clinical workflow and improve surgical outcomes.
  • Laparoscopic MasSpec Pen Design Three different laparoscopic/robotic MasSpec Pen tips were created from PDMS with diameters of 1.5 mm, 2.7 mm, and 4.0 mm. Grasping fins were built-in unilaterally in order to minimize overall cross section. Two micro-PTFE tubings (OD 0.794 mm, ID 0.339 mm) were grafted to the interior of the PDMS tip near the distal end. The micro-PTFE tubing was terminated 2 millimeters above the reservoir in order to avoid tissue interaction. The PDMS mixing solution from Dow Corning (Midland, Mich.) was molded into negative prints created by a Stratasys uPrint SE Plus 3D Printer (Eden Prairie, Minn., USA).
  • PTFE tubing was purchased from Sigma-Aldrich (St. Louis, Mich., USA), and silicone tubing was purchased from Saint Gobain (Tygon #3550, Malvern, Pa., USA).
  • This design allows the formation of a water droplet at the distal end of the PDMS tip that interacts with tissue to extract cellular lipids and small metabolites via phase diffusion.
  • This entire system was inserted into a laparoscopic simulation mannequin through a 10 mm HiCap 30107 H5 trocar by Karl Storz, (Tuttlingen, Germany). Images were taken with a wireless endoscope IP67 snake camera in the simulation mannequin.
  • Tissue Samples Human tissues were obtained from the Cooperative Human Tissue Network (CHTN) (Charlottesville, Va.) under approved Institutional Review Board protocol. Mouse brains were obtained from BioIVT (Westbury, N.Y., USA). Tissue samples were thawed to room temperature before analysis.
  • CHTN Cooperative Human Tissue Network
  • BioIVT Westbury, N.Y., USA
  • Mass Spectrometry Analysis Experiments were performed on a Q ExactiveTM Hybrid Quadrupole-OrbitrapTM mass spectrometer (Thermo Fisher Scientific, San Jose, Calif., USA). HPLC grade water was used for analysis. Full scan mode was carried out at the range of m/z 120 to 1800, at a resolving power of 140,000, capillary temperature was set to 350° C., and an S-lens radio frequency level was set to 100.
  • the MasSpec pen was also used to obtain samples from various materials to further evaluate the use of the pen is characterizing materials in the environment such a foods and forensic samples. Results demonstrated a wide range of further application for the mass spectroscopy analyses of the embodiments. For example, studies presented in FIGS. 22-25 and 30 demonstrated effect spectra could be produced from a wide range of food products including meats, fish and fruits. These spectra could be used to accurately characterize the source material for the samples, such the type of meat or fish that was being assessed. For these studies, meat and fish (salmon, trout, atlantic cod, and pollack) samples were obtained from a local supermarket (Central Market, Austin, Tex. Samples were stored in a fridge (4° C.) until analysis at room temperature.
  • the MasSpec Pen was used to analyze meat samples as well as 5 samples of each type of fish. Initial experiments were performed to optimize parameters of the MasSpec Pen for the highest lipid extraction and transmission. In the negative ion mode, detection of various glycerophospholipid species (GP), such as glycerophosphoinositols, glycerophosphoserines, and glycerophosphoethanolamines was achieved. In addition to GP, small metabolites, sphingolipids (SP), such as ceramides, and free fatty acids (FA), such as arachidonic acid and oleic acid were also observed. Despite the mass spectra complexity, the profiles obtained demonstrated trends in ion abundances characteristic of each meat sample.
  • GP glycerophospholipid species
  • SP sphingolipids
  • FA free fatty acids
  • the methods likewise can be used to detect and quantify the amounts of compounds present in materials. For example, in the case of forensic samples, the amount of illicit drugs could be accurately determined using a sampling taken by the MasSpec Pen (see, FIGS. 26 and 27 ). Likewise, the methods have been shown to be effective in detecting the presence of pesticides in source materials (see, FIGS. 28-29 ). Thus, methods of the embodiments can be effectively applied to characterize a wide range of materials and the determine and quantify the presence of compounds of interest in the materials.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Plasma & Fusion (AREA)
  • Robotics (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Endoscopes (AREA)
US16/882,801 2017-11-27 2020-05-26 Minimally invasive collection probe and methods for the use thereof Abandoned US20200305723A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16/882,801 US20200305723A1 (en) 2017-11-27 2020-05-26 Minimally invasive collection probe and methods for the use thereof
US17/453,740 US11737671B2 (en) 2017-11-27 2021-11-05 Minimally invasive collection probe and methods for the use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762591179P 2017-11-27 2017-11-27
US201862640385P 2018-03-08 2018-03-08
PCT/US2018/062625 WO2019104328A1 (en) 2017-11-27 2018-11-27 Minimally invasive collection probe and methods for the use thereof
US16/882,801 US20200305723A1 (en) 2017-11-27 2020-05-26 Minimally invasive collection probe and methods for the use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/062625 Continuation WO2019104328A1 (en) 2017-11-27 2018-11-27 Minimally invasive collection probe and methods for the use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/453,740 Continuation US11737671B2 (en) 2017-11-27 2021-11-05 Minimally invasive collection probe and methods for the use thereof

Publications (1)

Publication Number Publication Date
US20200305723A1 true US20200305723A1 (en) 2020-10-01

Family

ID=66630809

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/882,801 Abandoned US20200305723A1 (en) 2017-11-27 2020-05-26 Minimally invasive collection probe and methods for the use thereof
US17/453,740 Active US11737671B2 (en) 2017-11-27 2021-11-05 Minimally invasive collection probe and methods for the use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/453,740 Active US11737671B2 (en) 2017-11-27 2021-11-05 Minimally invasive collection probe and methods for the use thereof

Country Status (11)

Country Link
US (2) US20200305723A1 (he)
EP (1) EP3717901A4 (he)
JP (1) JP2021504703A (he)
CN (1) CN111566481A (he)
AU (1) AU2018373391A1 (he)
BR (1) BR112020010416A2 (he)
CA (1) CA3083260A1 (he)
IL (1) IL274759A (he)
MX (1) MX2020005448A (he)
SG (1) SG11202004568UA (he)
WO (1) WO2019104328A1 (he)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10943775B2 (en) 2016-09-02 2021-03-09 Board Of Regents, The University Of Texas System Collection probe and methods for the use thereof
US20210343515A1 (en) * 2017-06-08 2021-11-04 Board Of Regents, The University Of Texas System Systems and methods for microarray droplet ionization analysis
CN113842210A (zh) * 2021-08-02 2021-12-28 应葵 椎骨肿瘤微波消融手术仿真方法及装置
US20220257101A1 (en) * 2021-02-13 2022-08-18 Board Of Regents, The University Of Texas System Miniature hyperspectral imaging
US11737671B2 (en) 2017-11-27 2023-08-29 Board Of Regents, The University Of Texas System Minimally invasive collection probe and methods for the use thereof
US12121216B2 (en) * 2022-02-14 2024-10-22 Board Of Regents, The University Of Texas System Miniature hyperspectral imaging

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11219393B2 (en) 2018-07-12 2022-01-11 Trace Matters Scientific Llc Mass spectrometry system and method for analyzing biological samples
US12089932B2 (en) 2018-06-05 2024-09-17 Trace Matters Scientific Llc Apparatus, system, and method for transferring ions
EP3914891A4 (en) * 2019-01-25 2022-09-28 Board of Regents, The University of Texas System DEVICE AND METHOD FOR CLEANING AND/OR REPLACING MEDICAL DEVICES
US20230170202A1 (en) * 2020-04-27 2023-06-01 Board Of Regents, The University Of Texas System Detecting chemical compounds for forensic analysis
CA3177331A1 (en) * 2020-04-29 2021-11-04 Livia Schiavinato Eberlin Collecting and analyzing swab samples

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000829A1 (en) * 1987-07-23 1989-02-09 Terumo Kabushiki Kaisha Catheter tube
US5711816A (en) * 1990-07-06 1998-01-27 Advanced Technolgy Materials, Inc. Source reagent liquid delivery apparatus, and chemical vapor deposition system comprising same
US5119827A (en) 1990-09-05 1992-06-09 Board Of Regents, The University Of Texas System Mechanisms of antiestrogen resistance in breast cancer
US5100402A (en) 1990-10-05 1992-03-31 Megadyne Medical Products, Inc. Electrosurgical laparoscopic cauterization electrode
US5241990A (en) * 1992-07-10 1993-09-07 Inlet Medical, Inc. Irrigation/aspiration valve and probe for laparoscopy
US5470308A (en) 1992-08-12 1995-11-28 Vidamed, Inc. Medical probe with biopsy stylet
US5746720A (en) * 1995-10-18 1998-05-05 Stouder, Jr.; Albert E. Method and apparatus for insertion of a cannula and trocar
US5742050A (en) 1996-09-30 1998-04-21 Aviv Amirav Method and apparatus for sample introduction into a mass spectrometer for improving a sample analysis
US6297499B1 (en) 1997-07-17 2001-10-02 John B Fenn Method and apparatus for electrospray ionization
US6786884B1 (en) * 1999-10-29 2004-09-07 Bard Access Systems, Inc. Bolus tip design for a multi-lumen catheter
ATE386335T1 (de) 1999-10-29 2008-03-15 Mds Inc Through Its Mds Sciex Atmosphärendruckphotoionisation : ein neues ionisationsverfahren für flüssigchromatographie- massenspekrometrie
AU2002241535B2 (en) 2000-11-16 2006-05-18 Ciphergen Biosystems, Inc. Method for analyzing mass spectra
US6784439B2 (en) 2001-07-19 2004-08-31 Ut Battelle, Llc Thin-channel electrospray emitter
US20040014227A1 (en) * 2002-01-04 2004-01-22 Frederick Erik D. Apparatus, method and computer program product for automated high-throughput sampling and data acquisition
US6803566B2 (en) 2002-04-16 2004-10-12 Ut-Battelle, Llc Sampling probe for microarray read out using electrospray mass spectrometry
JP4095349B2 (ja) 2002-06-03 2008-06-04 ペンタックス株式会社 蛍光測定装置
US6677593B1 (en) 2002-08-28 2004-01-13 Ut-Battelle, Llc Planar flow-by electrode capacitive electrospray ion source
CA2433205A1 (en) 2003-03-18 2004-09-18 James Alexander Keenan Drug delivery, bodily fluid drainage, and biopsy device with enhanced ultrasonic visibility
US7684934B2 (en) 2003-06-06 2010-03-23 The United States Of America As Represented By The Department Of Health And Human Services Pattern recognition of whole cell mass spectra
US7335897B2 (en) 2004-03-30 2008-02-26 Purdue Research Foundation Method and system for desorption electrospray ionization
US7445603B2 (en) 2004-05-12 2008-11-04 Zkz Science Corp. Apparatus for removable distal internal cassette for in situ fixation and specimen processing with serial collection and storage of biopsy specimens
WO2006031842A2 (en) 2004-09-14 2006-03-23 Metara, Inc. In-process mass spectrometry with sample multiplexing
US7295026B2 (en) 2005-06-03 2007-11-13 Ut-Battelle, Llc Automated position control of a surface array relative to a liquid microjunction surface sampler
WO2006133325A2 (en) 2005-06-08 2006-12-14 Vanderbilt University Analysis of tissue samples surrounding malignancies
DE102005044307B4 (de) 2005-09-16 2008-04-17 Bruker Daltonik Gmbh Ionisierung desorbierter Moleküle
US7714276B2 (en) 2005-09-30 2010-05-11 New York University Methods for direct biomolecule identification by matrix-assisted laser desorption ionization (MALDI) mass spectrometry
DK1960014T3 (en) * 2005-12-14 2017-01-09 Stryker Corp Medical / surgical waste collection and disposal system
US7544933B2 (en) 2006-01-17 2009-06-09 Purdue Research Foundation Method and system for desorption atmospheric pressure chemical ionization
JP2009539114A (ja) 2006-05-26 2009-11-12 イオンセンス インコーポレイテッド 表面イオン化技術で用いるための固体を保持する器具
HU226837B1 (hu) 2006-05-31 2009-12-28 Semmelweis Egyetem Folyadéksugárral mûködõ deszorpciós ionizációs eljárás és eszköz
US7800056B2 (en) 2006-10-26 2010-09-21 Smiths Detection Montreal Inc. Document sampler and method of sampling a document
WO2008062372A2 (en) 2006-11-23 2008-05-29 Philips Intellectual Property & Standards Gmbh Device for separation and maldi analysis of an analyte in a sample
US7847244B2 (en) 2006-12-28 2010-12-07 Purdue Research Foundation Enclosed desorption electrospray ionization
US8232521B2 (en) 2007-02-02 2012-07-31 Waters Technologies Corporation Device and method for analyzing a sample
US20080243141A1 (en) 2007-04-02 2008-10-02 Salvatore Privitera Surgical instrument with separate tool head and method of use
EP2160570A4 (en) 2007-06-02 2012-12-05 Cerno Bioscience Llc SELF-CALIBRATION APPROACH FOR MASS SPECTROMETRY
WO2009088421A1 (en) 2008-01-03 2009-07-16 Board Of Regents, The University Of Texas System Non-invasive detection of bladder cancer by fluorescence in situ hybridization of aurora a
WO2009096903A1 (en) 2008-01-28 2009-08-06 National University Of Singapore Lipid tumour profile
WO2009109879A2 (en) * 2008-03-03 2009-09-11 Koninklijke Philips Electronics N.V. Biopsy guidance by electromagnetic tracking and photonic needle
US20110190151A1 (en) 2008-04-10 2011-08-04 Mcmanus Bruce Methods of diagnosing chronic cardiac allograft rejection
US8207494B2 (en) 2008-05-01 2012-06-26 Indiana University Research And Technology Corporation Laser ablation flowing atmospheric-pressure afterglow for ambient mass spectrometry
US8084735B2 (en) 2008-09-25 2011-12-27 Ut-Battelle, Llc Pulsed voltage electrospray ion source and method for preventing analyte electrolysis
WO2010039675A1 (en) 2008-09-30 2010-04-08 Prosolia, Inc. Method and apparatus for embedded heater for desorption and ionization of analytes
EP2711705A1 (en) 2008-12-19 2014-03-26 Medirista Biotechnologies AB Oxidized cardiolipin as a novel pro-inflammatory factor
US20100224013A1 (en) 2009-03-05 2010-09-09 Van Berkel Gary J Method and system for formation and withdrawal of a sample from a surface to be analyzed
WO2010114976A1 (en) 2009-04-01 2010-10-07 Prosolia, Inc. Method and system for surface sampling
SG10201401521UA (en) 2009-04-30 2014-07-30 Purdue Research Foundation Ion generation using wetted porous material
US9500572B2 (en) 2009-04-30 2016-11-22 Purdue Research Foundation Sample dispenser including an internal standard and methods of use thereof
US8704167B2 (en) 2009-04-30 2014-04-22 Purdue Research Foundation Mass spectrometry analysis of microorganisms in samples
CN105342646B (zh) * 2009-05-27 2019-06-28 英国质谱有限公司 用于鉴定生物组织的系统和方法
JP2012529058A (ja) 2009-06-03 2012-11-15 ウエイン・ステート・ユニバーシテイ レーザースプレーイオン化を用いる質量分析
EP2467868A1 (en) * 2009-08-17 2012-06-27 Temple University Of The Commonwealth System Of Higher Education Vaporization device and method for imaging mass spectrometry
US8546752B2 (en) 2009-12-07 2013-10-01 Advion Inc. Solid-phase extraction (SPE) tips and methods of use
AU2011214344A1 (en) 2010-02-11 2012-08-16 KATHOLIEKE UNIVERSITEIT LEUVEN, KULeuven R&D Phospholipid profiling and cancer
WO2011127091A1 (en) 2010-04-05 2011-10-13 Indiana University Research And Technology Corporation Method for enhancement of mass resolution over a limited mass range for time-of-flight spectrometry
JP5596402B2 (ja) 2010-04-19 2014-09-24 株式会社日立ハイテクノロジーズ 分析装置、イオン化装置及び分析方法
CN103038857B (zh) 2010-05-07 2016-01-20 Ut-巴特勒有限责任公司 从表面提取样品的系统和方法
CN201811941U (zh) 2010-05-26 2011-04-27 中国石油化工股份有限公司 液体样品解析电喷雾质谱desi-ms电离装置
US20130109592A1 (en) 2010-06-23 2013-05-02 University Of Louisville Research Foundation, Inc. Methods for detecting cancer
US20130131470A1 (en) 2010-07-14 2013-05-23 The Regents of the University of Colorado, a body coporate Methods and systems for in vivo clinical data measurement of analytes
US9153425B2 (en) 2010-09-01 2015-10-06 Ut-Battelle, Llc Device for high spatial resolution chemical analysis of a sample and method of high spatial resolution chemical analysis
EP2612345B1 (en) 2010-09-02 2020-04-08 University of the Sciences in Philadelphia System and method for ionization of molecules for mass spectrometry and ion mobility spectrometry
US8486703B2 (en) 2010-09-30 2013-07-16 Ut-Battelle, Llc Surface sampling concentration and reaction probe
WO2012058632A1 (en) 2010-10-29 2012-05-03 Thermo Fisher Scientific Oy Automated system for sample preparation and analysis
CN102221614B (zh) 2011-03-28 2013-07-17 山东大学 一种利用金纳米探针来鉴别小分子化合物作用靶点的分析方法
US9157921B2 (en) 2011-05-18 2015-10-13 Purdue Research Foundation Method for diagnosing abnormality in tissue samples by combination of mass spectral and optical imaging
US9546979B2 (en) 2011-05-18 2017-01-17 Purdue Research Foundation Analyzing a metabolite level in a tissue sample using DESI
US9024254B2 (en) 2011-06-03 2015-05-05 Purdue Research Foundation Enclosed desorption electrospray ionization probes and method of use thereof
WO2013098645A2 (en) * 2011-12-28 2013-07-04 Medimass, Ltd. System and method for rapid evaporative ionization of liquid phase samples
WO2013112680A1 (en) 2012-01-26 2013-08-01 University Of The Sciences In Philadelphia Ionization at intermediate pressure for atmospheric pressure ionization mass spectrometers
US20150008314A1 (en) 2012-01-26 2015-01-08 The Cleveland Clinic Foundation Diagnostic and prognostic biomarkers for cancer
US9105458B2 (en) 2012-05-21 2015-08-11 Sarah Trimpin System and methods for ionizing compounds using matrix-assistance for mass spectrometry and ion mobility spectrometry
JP2015522260A (ja) 2012-06-15 2015-08-06 ハリー スティリ， 疾患または状態を検出する方法
US20150226745A1 (en) 2012-09-20 2015-08-13 Tore Skotland Prostate cancer markers and uses thereof
CA2892822C (en) 2012-11-27 2023-08-08 Pontificia Universidad Catolica De Chile Compositions and methods for diagnosing thyroid tumors
WO2014106165A1 (en) 2012-12-30 2014-07-03 Brigham And Women's Hospital, Inc. System and method for analysis of bio-metabolites for-use in image-guided surgery
US10983126B2 (en) 2013-05-31 2021-04-20 The Brigham And Women's Hospital System and method for analyzing tissue for the presence of cancer using bio-marker profiles
CA2916977A1 (en) 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
FR3007634B1 (fr) * 2013-06-28 2016-09-02 Commissariat Energie Atomique Dispositif de prelevement in vivo d'especes biologiques et procede automatise d'analyse d'especes biologiques capturees au moyen d'un tel dispositif
KR102248457B1 (ko) * 2013-07-19 2021-05-04 스미스 디텍션 인크. 감소된 평균 유동을 가지는 질량 분석계 입구
JP6323922B2 (ja) * 2013-08-07 2018-05-16 ディーエイチ テクノロジーズ デベロップメント プライベート リミテッド 質量分析計供給源中への液体流れからの気泡除去
US9245722B2 (en) 2013-09-16 2016-01-26 Georgia Tech Research Corporation SMS probe and SEM imaging system and methods of use
US20160341712A1 (en) * 2013-10-23 2016-11-24 Brigham And Women's Hospital, Inc. System and method for analyzing tissue intra-operatively using mass spectrometry
US10395913B2 (en) 2013-12-30 2019-08-27 Purdue Research Foundation Mass spectrometry probes and systems for ionizing a sample transport
US20150202005A1 (en) * 2014-01-20 2015-07-23 Omniguide, Inc. System and Method To Control Surgical Energy Devices
JP2015171467A (ja) 2014-03-12 2015-10-01 セイコーエプソン株式会社 液体噴射装置および手術機器
US9297828B2 (en) 2014-03-27 2016-03-29 Ut-Battelle, Llc High heating rate thermal desorption for molecular surface sampling
US9595428B2 (en) 2014-06-17 2017-03-14 The Board Of Regents Of The University Oklahoma Cellular probe device, system and analysis method
US10000789B2 (en) 2014-06-17 2018-06-19 The Board Of Regents Of The University Of Oklahoma Cellular probe device, system and analysis method
US20160041138A1 (en) * 2014-08-11 2016-02-11 Arizona Board Of Regents On Behalf Of Arizona State University Methods for Monitoring Airborne Contaminants and Agents using Atmospheric Condensate
EP3265821B1 (en) * 2015-03-06 2021-06-16 Micromass UK Limited Liquid trap or separator for electrosurgical applications
EP3266035B1 (en) 2015-03-06 2023-09-20 Micromass UK Limited Collision surface for improved ionisation
EP3265797B1 (en) * 2015-03-06 2022-10-05 Micromass UK Limited Inlet instrumentation for ion analyser coupled to rapid evaporative ionisation mass spectrometry ("reims") device
US11239066B2 (en) 2015-03-06 2022-02-01 Micromass Uk Limited Cell population analysis
CN107580675B (zh) 2015-03-06 2020-12-08 英国质谱公司 拭子和活检样品的快速蒸发电离质谱（“reims”）和解吸电喷雾电离质谱（“desi-ms”）分析
GB2556994B (en) 2015-03-06 2021-05-12 Micromass Ltd Identification of bacterial strains in biological samples using mass spectrometry
US9632066B2 (en) 2015-04-09 2017-04-25 Ut-Battelle, Llc Open port sampling interface
US10060838B2 (en) 2015-04-09 2018-08-28 Ut-Battelle, Llc Capture probe
CN107923826B (zh) 2015-05-29 2022-03-08 普度研究基金会 用于分析组织样品的方法
GB201509402D0 (en) 2015-06-01 2015-07-15 Micromass Ltd Lock mass library for internal correction
WO2017049403A1 (en) 2015-09-22 2017-03-30 University Health Network System and method for optimized mass spectrometry analysis
US20170097355A1 (en) 2015-10-06 2017-04-06 University Of Washington Biomarkers and methods to distinguish ovarian cancer from benign tumors
GB2548596A (en) 2016-03-22 2017-09-27 Micromass Ltd An interface probe
WO2018013678A2 (en) 2016-07-13 2018-01-18 Board Of Regents, The University Of Texas System Molecular markers and methods for sample analysis via mass spectrometry
CN113834869A (zh) * 2016-09-02 2021-12-24 得克萨斯大学体系董事会 收集探针及其使用方法
WO2018045208A1 (en) 2016-09-02 2018-03-08 Board Of Regents, The University Of Texas System Collection probe and methods for the use thereof
US10492801B2 (en) * 2016-09-20 2019-12-03 Osteomed Llc Power driven surgical tool
CA3083260A1 (en) 2017-11-27 2019-05-31 Board Of Regents, The University Of Texas System Minimally invasive collection probe and methods for the use thereof
WO2019165351A1 (en) 2018-02-23 2019-08-29 Board Of Regents, The University Of Texas System Tissue analysis by mass spectrometry

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10943775B2 (en) 2016-09-02 2021-03-09 Board Of Regents, The University Of Texas System Collection probe and methods for the use thereof
US11239065B2 (en) 2016-09-02 2022-02-01 Board Of Regents, The University Of Texas System Collection probe and methods for the use thereof
US11756778B2 (en) 2016-09-02 2023-09-12 Board Of Regents, The University Of Texas System Collection probe and methods for the use thereof
US12087566B2 (en) 2016-09-02 2024-09-10 Board Of Regents, The University Of Texas System Collection probe and methods for the use thereof
US20210343515A1 (en) * 2017-06-08 2021-11-04 Board Of Regents, The University Of Texas System Systems and methods for microarray droplet ionization analysis
US11737671B2 (en) 2017-11-27 2023-08-29 Board Of Regents, The University Of Texas System Minimally invasive collection probe and methods for the use thereof
US20220257101A1 (en) * 2021-02-13 2022-08-18 Board Of Regents, The University Of Texas System Miniature hyperspectral imaging
CN113842210A (zh) * 2021-08-02 2021-12-28 应葵 椎骨肿瘤微波消融手术仿真方法及装置
US12121216B2 (en) * 2022-02-14 2024-10-22 Board Of Regents, The University Of Texas System Miniature hyperspectral imaging

Also Published As

Publication number Publication date
BR112020010416A2 (pt) 2020-12-15
WO2019104328A1 (en) 2019-05-31
MX2020005448A (es) 2020-08-27
IL274759A (he) 2020-07-30
US11737671B2 (en) 2023-08-29
CN111566481A (zh) 2020-08-21
AU2018373391A1 (en) 2020-06-11
SG11202004568UA (en) 2020-06-29
US20220296102A1 (en) 2022-09-22
EP3717901A4 (en) 2021-08-25
CA3083260A1 (en) 2019-05-31
EP3717901A1 (en) 2020-10-07
JP2021504703A (ja) 2021-02-15

Similar Documents

Publication Publication Date Title
US11737671B2 (en) Minimally invasive collection probe and methods for the use thereof
US11239065B2 (en) Collection probe and methods for the use thereof
US20100081928A1 (en) Histological Facilitation systems and methods
US20220196697A1 (en) Apparatus and methods for cleaning and/or exchanging medical devices
US20220268784A1 (en) Using mass spectrometry to identify endometriosis tissue
WO2018045208A1 (en) Collection probe and methods for the use thereof
NZ791450A (en) Collection probe and methods for the use thereof
BR112019004261B1 (pt) Aparelho para a obtenção de amostras para a análise de espectrometria de massa

Legal Events

Date Code Title Description
AS Assignment

Owner name: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, TEXAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHIAVINATO EBERLIN, LIVIA;MILNER, THOMAS;ZHANG, JIALING;AND OTHERS;SIGNING DATES FROM 20181129 TO 20190909;REEL/FRAME:053311/0952

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION